Lung Cancer Liquid Biopsy Market Size, Share, Trends, Growth Outlook

Lung Cancer Liquid Biopsy Market is estimated to increase at a growth rate of 17.5% CAGR over the forecast period from 2024 to 2030.

The global Lung Cancer Liquid Biopsy Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Biomarker (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers, Others).

An Introduction to Lung Cancer Liquid Biopsy Market Market in 2024

The Lung Cancer Liquid Biopsy Market comprises liquid biopsy tests, diagnostic assays, and molecular testing technologies used in oncology, cancer diagnostics, and precision medicine for detecting lung cancer, monitoring cancer progression, and analyzing tumor biomarkers in liquid biopsy samples such as blood, plasma, or serum. Lung cancer liquid biopsy offers non-invasive cancer detection, genetic mutation analysis, and treatment response monitoring, providing oncologists, pathologists, and healthcare providers with personalized cancer diagnostics, targeted therapy selection, and disease monitoring solutions for lung cancer patients. Market dynamics include liquid biopsy technologies, cancer biomarkers, molecular diagnostics, and liquid biopsy assay innovations for advanced cancer diagnostics and therapeutic interventions.

Lung Cancer Liquid Biopsy Market Competitive Landscape

The global Lung Cancer Liquid Biopsy Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Lung Cancer Liquid Biopsy Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Lung Cancer Liquid Biopsy Industry include- Agilent Technologies Inc, Bio-Rad Laboratories Inc, Cardiff Oncology Inc, CareDx, Eurofins Scientific, Exact Sciences Corp, Exosome Diagnostics Inc, F. Hoffmann-La Roche Ltd, Genomic Health Inc, Guardant Health, Illumina Inc, Immucor, LungLife AI Inc, MDxHealth, Menarini Silicon Biosystems, Myriad Genetics Inc, Natera Inc, QIAGEN N.V., Thermo Fisher Scientific Inc.

Lung Cancer Liquid Biopsy Market Trend: Rapid Adoption of Liquid Biopsy Technologies

A prominent trend in the market for lung cancer liquid biopsy is the rapid adoption of liquid biopsy technologies for non-invasive cancer detection and monitoring. Liquid biopsy, a minimally invasive diagnostic approach that analyzes circulating tumor DNA (ctDNA), RNA, and other biomarkers in blood samples, has gained traction as a valuable tool in the management of lung cancer. Unlike traditional tissue biopsies, liquid biopsies offer several advantages, including accessibility, repeatability, and real-time monitoring of tumor dynamics, making them particularly useful for guiding treatment decisions, monitoring treatment response, and detecting early signs of disease recurrence. This trend reflects the increasing recognition of liquid biopsy as a complementary diagnostic modality to tissue biopsy in lung cancer care, driving market growth and innovation in the field of liquid biopsy technologies.

Lung Cancer Liquid Biopsy Market Driver: Demand for Personalized Treatment Strategies

The market for lung cancer liquid biopsy is driven by the demand for personalized treatment strategies based on molecular profiling and tumor heterogeneity. Lung cancer is a heterogeneous disease characterized by diverse genetic alterations and molecular subtypes, each requiring tailored treatment approaches for optimal outcomes. Liquid biopsy enables the detection of tumor-specific mutations, gene rearrangements, and expression profiles from peripheral blood samples, facilitating the identification of actionable targets and the selection of targeted therapies, immunotherapies, and combination regimens personalized to individual patient profiles. With the growing emphasis on precision medicine and targeted therapies in oncology, there is a strong market demand for liquid biopsy assays that offer comprehensive genomic profiling, high sensitivity, and rapid turnaround times, driving adoption rates and market expansion in lung cancer management.

Lung Cancer Liquid Biopsy Market Opportunity: Integration of Artificial Intelligence and Machine Learning

A Market Opportunity in the market for lung cancer liquid biopsy lies in the integration of artificial intelligence (AI) and machine learning (ML) algorithms for data analysis and interpretation. As the volume and complexity of genomic data generated from liquid biopsy assays continue to increase, there is a need for advanced bioinformatics tools and computational algorithms capable of extracting meaningful insights, identifying clinically relevant biomarkers, and predicting treatment responses. AI and ML technologies offer the potential to enhance the accuracy, efficiency, and reproducibility of liquid biopsy data analysis, enabling clinicians to make more informed decisions regarding patient management and therapy selection. By leveraging AI-driven platforms, bioinformatics pipelines, and predictive modeling algorithms, companies can develop innovative solutions that streamline data analysis workflows, improve diagnostic accuracy, and facilitate precision oncology initiatives in lung cancer care. Collaboration with data scientists, bioinformaticians, and clinical researchers can accelerate the development and commercialization of AI-powered liquid biopsy solutions, unlocking new opportunities for market differentiation and growth in the field of lung cancer diagnostics and therapeutics.

Lung Cancer Liquid Biopsy Market Share Analysis: Lung Cancer Liquid Biopsy Utilizing ctDNA (Circulating Tumor DNA) is the fastest growing market segment over the forecast period to 2030

Among the various biomarkers used in lung cancer liquid biopsy, the segment experiencing rapid growth is ctDNA (Circulating tumor DNA). ctDNA analysis involves the detection and analysis of tumor-derived DNA fragments circulating in the bloodstream, offering a minimally invasive and accessible method for monitoring disease progression and treatment response in patients with lung cancer. The adoption of ctDNA-based liquid biopsy techniques has surged due to their ability to provide real-time information on tumor heterogeneity, genetic mutations, and resistance mechanisms, thus guiding personalized treatment decisions. In particular, ctDNA analysis has shown significant promise in both small cell lung cancer and non-small cell lung cancer, enabling early detection of disease recurrence, assessment of treatment efficacy, and identification of potential therapeutic targets. Diagnostic and imaging centers, hospitals, academic and research centers, and other healthcare facilities are increasingly incorporating ctDNA-based liquid biopsy into their oncology practices, reflecting the growing recognition of its clinical utility and value in lung cancer management. As research continues to advance and technology improves, ctDNA-based liquid biopsy is poised to play an increasingly prominent role in the diagnosis, prognosis, and treatment of lung cancer, driving its rapid growth in the field of oncology diagnostics.

Lung Cancer Liquid Biopsy Market Segmentation

By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Lung Cancer Liquid Biopsy Companies

Agilent Technologies Inc
Bio-Rad Laboratories Inc
Cardiff Oncology Inc
CareDx
Eurofins Scientific
Exact Sciences Corp
Exosome Diagnostics Inc
F. Hoffmann-La Roche Ltd
Genomic Health Inc
Guardant Health
Illumina Inc
Immucor
LungLife AI Inc
MDxHealth
Menarini Silicon Biosystems
Myriad Genetics Inc
Natera Inc
QIAGEN N.V.
Thermo Fisher Scientific Inc
* List not Exhaustive

Reasons to Buy the Lung Cancer Liquid Biopsy Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Lung Cancer Liquid Biopsy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Lung Cancer Liquid Biopsy Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Lung Cancer Liquid Biopsy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Lung Cancer Liquid Biopsy Market Size Outlook, $ Million, 2021 to 2030
3.2 Lung Cancer Liquid Biopsy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Lung Cancer Liquid Biopsy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Lung Cancer Liquid Biopsy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Lung Cancer Liquid Biopsy Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Lung Cancer Liquid Biopsy Industry
4.2 Key Market Trends in Lung Cancer Liquid Biopsy Industry
4.3 Potential Opportunities in Lung Cancer Liquid Biopsy Industry
4.4 Key Challenges in Lung Cancer Liquid Biopsy Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Lung Cancer Liquid Biopsy Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Lung Cancer Liquid Biopsy Market Outlook by Segments
7.1 Lung Cancer Liquid Biopsy Market Outlook by Segments, $ Million, 2021- 2030
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
8 North America Lung Cancer Liquid Biopsy Market Analysis and Outlook To 2030
8.1 Introduction to North America Lung Cancer Liquid Biopsy Markets in 2024
8.2 North America Lung Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Lung Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
9 Europe Lung Cancer Liquid Biopsy Market Analysis and Outlook To 2030
9.1 Introduction to Europe Lung Cancer Liquid Biopsy Markets in 2024
9.2 Europe Lung Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Lung Cancer Liquid Biopsy Market Size Outlook by Segments, 2021-2030
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
10 Asia Pacific Lung Cancer Liquid Biopsy Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Lung Cancer Liquid Biopsy Markets in 2024
10.2 Asia Pacific Lung Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Lung Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
11 South America Lung Cancer Liquid Biopsy Market Analysis and Outlook To 2030
11.1 Introduction to South America Lung Cancer Liquid Biopsy Markets in 2024
11.2 South America Lung Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Lung Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
12 Middle East and Africa Lung Cancer Liquid Biopsy Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Lung Cancer Liquid Biopsy Markets in 2024
12.2 Middle East and Africa Lung Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Lung Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Agilent Technologies Inc
Bio-Rad Laboratories Inc
Cardiff Oncology Inc
CareDx
Eurofins Scientific
Exact Sciences Corp
Exosome Diagnostics Inc
F. Hoffmann-La Roche Ltd
Genomic Health Inc
Guardant Health
Illumina Inc
Immucor
LungLife AI Inc
MDxHealth
Menarini Silicon Biosystems
Myriad Genetics Inc
Natera Inc
QIAGEN N.V.
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others